IP Library Granted Patent US 10,338,084
Granted Patent B2
US 10,338,084 · App. 15/482,332 · Granted Jul 2, 2019

Processing reagent and use thereof in assays for detection of analytes associated with a binding protein

Inventors: Richard L. Egan (Oceanside, CA); Judson McFarland (San Diego, CA); Mark Renshaw (San Diego, CA)
Assignee: Quidel Corporation
G01N33/82
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,338,084
App. No.
15/482,332
Granted
Jul 2, 2019
Kind
B2
Abstract

Methods for preparing a sample for detection of an analyte of interest that is bound in vivo to a protein are provided. The method comprises providing a processing reagent comprising metaperiodate and contacting a sample suspected of comprising an analyte of interest associated with a protein with the processing reagent to form a mixture. The analyte of interest, if present in the sample (or mixture), is separated from its associated protein for detection of the analyte of interest. In one embodiment, the method is applied to samples for the detection of levels of vitamin D circulating in the blood. Samples are processed using the reagent disclosed herein to separate the analyte of interest, vitamin D or a metabolite thereof, from the vitamin D binding protein and/or albumin, for detection of the analyte separated from its binding protein(s).

Claims (15)

1. A method to process and assay a sample, comprising:

providing a sample suspected of comprising vitamin D or a metabolite of vitamin D each bound to a binding protein;

contacting the sample with a processing reagent comprising between about 0.2 M to about 0.45 M metaperiodate at a ratio of between about 1:2 and 1:12 to form a mixture;

exposing the mixture to a catalyst that is heat or a manganese salt; and

assaying the mixture by performing an immunoassay comprising contacting an aliquot of the mixture with an antibody that specifically binds vitamin D or vitamin D metabolite to detect vitamin D or vitamin D metabolite in the sample, wherein exposing the mixture to a catalyst that is heat comprises incubating the mixture at a temperature above 25° C. and less than 90° C.

2. The method of claim 1 , wherein the contacting and the exposing occur sequentially.

3. The method of claim 1 , wherein the contacting and the exposing occur essentially simultaneously.

4. The method of claim 1 , wherein the sample is exposed to the manganese salt in the contacting step by contacting the sample with a processing reagent comprising metaperiodate and the manganese salt.

5. The method of claim 1 , wherein the mixture is contacted with a solution comprising the manganese salt.

6. The method of claim 1 , wherein the catalyst is a manganese salt.

7. The method of claim 6 , wherein the manganese salt is manganese chloride.

8. The method of claim 1 , wherein contacting comprises contacting the sample with a processing reagent comprising the metaperiodate in the form of a metaperiodate anion intermittently associated with a cation of sodium.

9. A method to detect presence of vitamin D or a metabolite of vitamin D in a blood sample, comprising:

combining a blood sample with a solution comprising between about 0.2 M to about 0.45 M metaperiodate and manganese salt to form a mixture;

detecting vitamin D or a metabolite of vitamin D in the mixture by performing an immunoassay comprising contacting an aliquot of the mixture with an antibody that specifically binds vitamin D or vitamin D metabolite, wherein the ratio of the blood sample to the solution is between about 1:4 and 1:10.

Assignments (7)
SECURITY AGREEMENT Recorded Aug 22, 2025
From: CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; QUIDEL CARDIOVASCULAR INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 072526/0643 →
RELEASE (REEL 060220 / FRAME 0711) Recorded Aug 22, 2025
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
Reel/Frame 072577/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2024
From: QUIDEL CORPORATION
To: ORTHO-CLINICAL DIAGNOSTICS, INC.
Reel/Frame 068657/0827 →
SECURITY AGREEMENT Recorded May 31, 2022
From: QUIDEL CORPORATION; BIOHELIX CORPORATION; DIAGNOSTIC HYBRIDS, INC.; QUIDEL CARDIOVASCULAR INC.; ORTHO-CLINICAL DIAGNOSTICS, INC.; CRIMSON U.S. ASSETS LLC; CRIMSON INTERNATIONAL ASSETS LLC; MICRO TYPING SYSTEMS, INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 060220/0711 →
RELEASE OF SECURITY INTEREST Recorded May 31, 2022
From: BANK OF AMERICA, N.A.
To: QUIDEL CORPORATION
Reel/Frame 060220/0649 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 21, 2017
From: MCFARLAND, JUDSON; RENSHAW, MARK; EGAN, RICHARD L.
To: QUIDEL CORPORATION
Reel/Frame 043918/0324 →
SECURITY INTEREST Recorded Oct 6, 2017
From: QUIDEL CORPORATION
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 044141/0686 →
Continuity (2)
Provisional Application 62319690 · Apr 7, 2016
Related Publication 20170292964A1 · Oct 12, 2017